Details

Autor(en) / Beteiligte

• Mujahid, Khizra
• Rana, Isra
• Suliman, Ivan Hardianto
• Li, Zhen
• Wu, Jiang
• He, Huacheng
• Nam, Jutaek

Titel

Biomaterial-Based Sustained-Release Drug Formulations for Localized Cancer Immunotherapy

Ist Teil von

• ACS applied bio materials, 2024-08, Vol.7 (8), p.4944-4961

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Cancer immunotherapy has revolutionized clinical cancer treatments by taking advantage of the immune system to selectively and effectively target and kill cancer cells. However, clinical cancer immunotherapy treatments often have limited efficacy and/or present severe adverse effects associated primarily with their systemic administration. Localized immunotherapy has emerged to overcome these limitations by directly targeting accessible tumors via local administration, reducing potential systemic drug distribution that hampers drug efficacy and safety. Sustained-release formulations can prolong drug activity at target sites, which maximizes the benefits of localized immunotherapy to increase the therapeutic window using smaller dosages than those used for systemic injection, avoiding complications of frequent dosing. The performance of sustained-release formulations for localized cancer immunotherapy has been validated preclinically using various implantable and injectable scaffold platforms. This review introduces the sustained-release formulations developed for localized cancer immunotherapy and highlights their biomaterial-based platforms for representative classes, including inorganic scaffolds, natural hydrogels, synthetic hydrogels, and microneedle patches. The design rationale and other considerations are summarized for further development of biomaterials for the construction of optimal sustained-release formulations.